Docket No.: PB-0003 USN

- 2. (Once Amended) A substantially purified polynucleotide, comprising a polynucleotide sequence selected from:
 - (a) a polynucleotide sequence selected from the group consisting of SEQ/ID NOs: 1-5;
 - (b) a polynucleotide sequence which encodes the polypeptide sequence of SEQ ID NO:

6;

- (c) a polynucleotide sequence which is completely complementary to the polynucleotide sequence of (a) or (b); and
- (d) A naturally-occurring variant of the polynucleotide of (a), (b), or (c), having at least 95% identity to the polynucleotide sequence of (a), (b), or (c).
- 4. (Once Amended) A substantially purified polypeptide, comprising a polypeptide sequence selected from:

 B^{Z}

- (a) the polypeptide sequence of SEQ ID NO. 6;
- (b) a polypeptide sequence comprising at least 6 sequential amino acids of the polypeptide sequence of (a); and
- (c) a variant of the polypeptide sequence of SEQ ID NO:6 having at least 95% identity to the polypeptide sequence of SEQ ID NO:6.
 - 5. An expression vector comprising the polynucleotide of claim 2.
 - 6. A host cell comprising the expression vector of claim 5.
- 7. (Once Amended) A composition comprising the polynucleotide of claim 2 in conjunction with a suitable pharmaceutical carrier.

33

- 8. (Once Amended) A composition comprising the polypeptide of claim 4 in conjunction with a suitable pharmaceutical carrier.
 - 9. An antibody which specifically binds to the polypeptide of claim 4.
- 10. A method for diagnosing a disease or condition associated with the altered expression of a gene that is coexpressed with one or more neurotransmitter-processing-specific genes, wherein each neurotransmitter-processing-specific gene is selected from the group consisting of L-tyrosine hydroxylase (TH), aromatic amino acid decarboxylase (AADC), dopamine β-hydroxylase (DBH), nicotinic acetylcholine receptor α3 subunit precursor (nAchR-α3), secretogranin I and II, Rab3a,

103375

Docket No.: PB-0003 USN

human cocaine and amphetamine regulated transcript (hCART), vesicular monoamine transporter 1 (hVMAT1), and ARIX homeodomain protein, the method comprising the steps of:

- (a) providing a sample comprising one of more of said coexpressed genes;
- (b) hybridizing the polynucleotide of claim 2 to said coexpressed genes under conditions effective to form one or more hybridization complexes; and
 - (c) detecting the hybridization complexes, wherein the presence of the hybridization complexes correlates with the presence of the disease or condition.
- 12. (New) A composition comprising a plurality of polynucleotides wherein the polynucleotides consist of the nucleic acid sequences of SEQ ID NOs:1-5 or the complements thereof.
 - 13 (New) The composition of claim 12 and a labeling moiety.
- 14. (New) A method for using a polynucleotide to detect gene expression in a sample, the method comprising:
- a) hybridizing the composition of claim 13 to a sample thereby forming at least one hybridization complex;
- b) detecting complex formation, wherein complex formation indicates gene expression in the sample.
- 15. (New) The method of claim 14 wherein gene expression is compared to standards and is diagnostic of Parkinson's disease, schizophrenia, or epilepsy.

